Immunome Inc reports results for the quarter ended June 30 - Earnings Summary

Immunome

11/08/2025 13:00

Immunome Inc IMNM.OQ reported a quarterly adjusted loss of 50 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -60 cents.  The mean expectation of nine analysts for the quarter was for a loss of 53 cents per share. Wall Street expected results to range from -59 cents to -44 cents per share.

Revenue rose 69.8% to $4.02 million from a year ago; analysts expected $714.29 thousand.

Immunome Inc's reported EPS for the quarter was a loss of 50 cents​.

The company reported a quarterly loss of $43.4 million.

Immunome Inc shares had risen by 4.2% this quarter and lost 8.8% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 15.2% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Immunome Inc is $22.00, about 56% above its last closing price of $9.69

This summary was machine generated from LSEG data August 11 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.53
-0.50
Beat
Mar. 31 2025
-0.68
-0.52
Beat
Dec. 31 2024
-0.58
-1.28
Missed
Sep. 30 2024
-0.56
-0.78
Missed